Ethinylestradiol/drospirenone/folic acid

Drug Profile

Ethinylestradiol/drospirenone/folic acid

Alternative Names: BAY98-7071; Beyaz; EE20/DRSP/L-5MTHF; ethinylestradiol/drospirenone/methyltetrahydrofolate; Safyral; Yasmin Plus; Yaz Flex Plus; Yaz Plus

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bayer
  • Class Alkylated estrogenic steroids; Androstenes; Antiandrogens; Estradiol congeners; Estrenes; Folic-acids; Hormonal contraceptives; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Vitamins
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris; Pregnancy; Premenstrual dysphoric disorder

Most Recent Events

  • 20 Jul 2015 No recent reports on development identified - Preregistration for Pregnancy (Prevention) in Europe (PO)
  • 01 Feb 2015 Bayer completes a phase III trial in Contraception in Mexico (NCT01902264)
  • 15 Aug 2013 Phase-III clinical trials in Contraception/Pregnancy (Prevention) in Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top